Essa Pharma’s sole clinical-stage candidate was on track to fall short against Xtandi in a phase 2 prostate cancer trial, ...

Distalmotion has grabbed hold of a de novo clearance for its Dexter surgical robot, a system designed for hospitals as well ...

Two decades ago, when two genetic mutations were discovered in Asia that gave scientists a better idea of how pain sensations ...

Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...

Roche put forward new data on two of its upcoming, non-invasive blood tests designed to help rule out a diagnosis of ...

AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The acquisition will give AbbVie control of an Alzheimer’s ...

The asset at play is fipaxalparant, a candidate designed to block the lysophosphatidic acid receptor 1 (LPAR1). Amgen tested ...

As the world of neurodegenerative disease drug development continues to be roiled by controversies, one company has taken a ...

A randomized trial of patients with a narrowing of their heart’s aortic valve, but who had not yet begun to show the symptoms ...

The Boston-based company acquired apraglutide last year through a $1 billion takeover of VectaBio. Ironwood believes the ...

Compass Pathways’ journey to phase 3 psychedelic depression data is taking longer than expected. | Compass Pathways’ journey to phase 3 psychedelic depression data is taking longer than expected. With ...

Israeli computational biology company Evogene is looking to the clouds to secure the computational power it needs to develop ...